Plus   Neg

Achillion Pharmaceuticals (ACHN) Rose To A 3-Month High On EMA Opinion

Achillion Pharmaceuticals Inc. (ACHN) announced Monday morning that its ACH-4471 received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for orphan status in the European Union.

Achillion Pharmaceuticals gapped up at the open Monday and climbed for the majority of the morning. Shares finished with a gain of 0.45 at $3.41 on above average volume. The stock broke out to a 3-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT